New bronchodilators. 3. Imidazo[4,5-c][1,8]naphthyridin-4(5H)-ones
作者:Fumio Suzuki、Takeshi Kuroda、Takashi Kawakita、Haruhiko Manabe、Shigeto Kitamura、Kenji Ohmori、Michio Ichimura、Hiroshi Kase、Shunji Ichikawa
DOI:10.1021/jm00104a013
日期:1992.12
imidazol[4,5-c][1,8]naphthyridin-4(5H)-ones 5 were designed and synthesized. Some of these new heterocycles exhibited more potent bronchodilator activity in vitro and in vivo than theophylline. With respect to modification at the 5-position, both phenyl and n-butyl substitution produced potent activity. Though bulk tolerance at N-3 is observed with short and small lipophilic groups, any substitution at the
为了开发新的口服支气管扩张剂,设计并合成了一系列新型的咪唑[4,5-c] [1,8]萘啶-4(5H)-ones 5。这些新杂环中的一些在体外和体内比茶碱表现出更强的支气管扩张活性。关于在5-位的修饰,苯基和正丁基取代均产生有效的活性。尽管在短和小的亲脂基团上观察到了在N-3处的体积耐受性,但亲本骨架的其他位置的任何取代和转化都消除了活性。因此,选择了满足这些条件的5-苯基-1H-咪唑并[4,5-c] [1,8]萘啶-4(5H)-一(23)(KF17625)进行进一步研究(抗原吸入诱导支气管痉挛模型;最小有效剂量(MED)= 1 mg / kg,口服;抗原诱导的气管收缩(Schultz-Dale反应),IC50 = 2.2 microM)。在豚鼠分离的气管制剂中,化合物23抑制了卡巴胆碱,组胺或白三烯D4诱导的收缩和松弛的自发音调,其效力比氨茶碱高4至16倍。因此,它似乎直接放松了气道平滑肌。23对10